celecoxib has been researched along with aspartic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jung, Y; Kang, S; Kim, DD; Kim, H; Kim, J; Kim, YM; Lee, Y; Yoon, JH | 1 |
| Jeong, SH; Jung, Y; Kim, H; Kim, W; Lee, Y; Yoon, JH | 1 |
2 other study(ies) available for celecoxib and aspartic acid
| Article | Year |
|---|---|
N-succinylaspart-1-yl celecoxib is a potential colon-specific prodrug of celecoxib with improved therapeutic properties.
Topics: Administration, Oral; Animals; Aspartic Acid; Celecoxib; Chromatography, High Pressure Liquid; Colon; Cyclooxygenase 2 Inhibitors; Intestinal Absorption; Intestine, Small; Male; Prodrugs; Pyrazoles; Rats; Rats, Sprague-Dawley; Spectrum Analysis; Sulfonamides | 2012 |
Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis.
Topics: 6-Ketoprostaglandin F1 alpha; Adenomatous Polyposis Coli; Animals; Aspartic Acid; Cecum; Celecoxib; Chemistry Techniques, Synthetic; Chromatography, High Pressure Liquid; Colon; Cyclooxygenase 2 Inhibitors; Drug Delivery Systems; Drug Stability; Glutamates; Intestinal Absorption; Male; Molecular Structure; Prodrugs; Pyrazoles; Rats; Rats, Sprague-Dawley; Solubility; Sulfonamides; Tissue Distribution | 2012 |